Germline TSC1 or TSC2 mutations cause tuberous sclerosis complex (TSC), a hamartoma syndrome with lung involvement. To explore the potential interaction between TSC1 and KRAS activation in lung cancer, mice in which Tsc1 loss and Kras G12D expression occur in a small fraction of lung epithelial cells were generated. Mice with a combined Tsc1-Kras G12D mutation had dramatically reduced tumor latency (median survival: 11.6-15.6 weeks) in comparison with Kras G12D alone mutant mice (median survival: 27.5 weeks). Tsc1-Kras G12D tumors showed consistent activation of mTOR (mammalian target of rapamycin)C1 and responded to treatment with rapamycin, leading to significantly improved survival, whereas rapamycin had minor effects on cancers in Kras G12D alone mice. Loss of heterozygosity for TSC1 or TSC2 was found in 22% of 86 human lung cancer specimens. However, none of the 80 lung cancer lines studied showed evidence of the lack of expression of either TSC1 or TSC2 or a signaling pattern corresponding to complete loss. These data indicate that Tsc1 loss synergizes with the Kras mutation to enhance lung tumorigenesis in the mouse, but that this is a rare event in human lung cancer. Rapamycin may have unique benefit for patients with lung cancer, for whom the TSC1/TSC2 function is limited. Oncogene (2010Oncogene ( ) 29, 1588Oncogene ( -1597 doi:10.1038/onc.2009 published online 7 December 2009 Keywords: lung cancer; TSC1; KRAS; TSC2; mTOR
Introduction
Lung cancer is the leading cause of cancer-related deaths in both the United States and worldwide (Jemal et al., 2008; Molina et al., 2008) . Non-small cell lung cancer (NSCLC) accounts for 80% of all cases. In NSCLC, several proto-oncogenes, such as KRAS and EGFR, are known to be mutated at significant frequency (Thomas et al., 2007; Ding et al., 2008; Molina et al., 2008) . In addition, loss of tumor-suppressor gene function is known to occur in NSCLC (Weir et al., 2007; Ding et al., 2008) . To dissect the role of tumor-suppressor genes in lung tumorigenesis, we generated a series of murine models using an activatable Kras G12D allele (Jackson et al., 2001 ) and conditional alleles of several different tumor-suppressor genes, such as p53, p16
Ink4a
, Ink4a/arf and Lkb1 . Among these, loss of Lkb1 had the most potent effect in accelerating lung tumorigenesis, and led to several different histological subtypes, as well as invasion and metastasis . LKB1 inactivation also occurs in up to 35% of human lung cancers Sanchez-Cespedes, 2007; Ding et al., 2008) . LKB1 is a serine/threonine kinase that has multiple targets, including adenosine monophosphate-activated protein kinase, which phosphorylates and activates the TSC1/TSC2 complex (Corradetti et al., 2004; Shaw et al., 2004; Hardie and Sakamoto, 2006) .
The TSC1/TSC2 complex is the only known GTPase for Rheb, serving to reduce Rheb-GTP levels, and thereby inhibit the activation of mammalian target of rapamycin (mTOR)C1, a protein complex consisting of mTOR, RAPTOR and mLST8 (Guertin and Sabatini, 2007; . TSC1 and TSC2 are targets of multiple kinases, which regulate the GTPase activity of the complex, and thus they function as critical integrators of growth signals within the cell. Loss of either TSC1 or TSC2 prevents the formation of a functional TSC1/TSC2 complex, resulting in constitutive activation of mTORC1 and phosphorylation of its downstream targets S6K and 4E-BP1, with net effects of abnormal translational activation leading to cell growth and proliferation (Guertin and Sabatini, 2007; .
Germline mutations of TSC1 or TSC2 result in tuberous sclerosis complex (TSC), an autosomal dominant tumor-suppressor gene syndrome that is characterized by widespread hamartoma development (Crino et al., 2006) . Pulmonary manifestations of TSC include lymphangioleiomyomatosis and multifocal micronodular pneumocyte hyperplasia, although lung cancer is rare in TSC patients (Muir et al., 1998; McCormack, 2008) .
As Lkb1 loss synergized with Kras activation to accelerate tumorigenesis in the mouse , we hypothesized that part or all of this effect was due to the loss of adenosine monophosphate-activated protein kinase activation by LKB1, leading to functional inactivation of the TSC1/TSC2 complex and downstream mTORC1 activation (Corradetti et al., 2004; Shaw et al., 2004) . To examine this hypothesis in vivo, we generated a novel lung adenocarcinoma murine model by intercrossing the conditional oncogenic LSLKras G12D allele (Jackson et al., 2001 ) and the conditional Tsc1 null allele (Kwiatkowski et al., 2002) . Strikingly, homozygous or heterozygous loss of Tsc1 dramatically accelerated Kras
G12D
-driven lung cancer development. In addition, the mTORC1 inhibitor rapamycin seemed to have unique benefit in inducing tumor regression and extending survival in Tsc1-Kras G12D mice. We then examined the potential role of the TSC1/TSC2 complex in human lung cancer development using both direct patient specimens, and a panel of 80 NSCLC cell lines. A significant fraction of human lung cancer samples showed evidence of TSC1 or TSC2 LOH, mainly TSC1 LOH. However, none of the cell lines showed evidence of complete loss of TSC1 or TSC2, suggesting that this event is rare in vivo in patients.
Results
The Kras G12D mutation synergizes with Tsc1 loss in the bronchial epithelium leading to accelerated lung cancer development and early mortality To generate mice with both expression of Kras G12D and loss of Tsc1 in the lung epithelium, we crossed mice bearing the Lox-Stop-Lox Kras G12D (hereafter known as LSL-Kras G12D ) allele (Jackson et al., 2001) to Tsc1 L/L mice (Kwiatkowski et al., 2002) . Mice bearing different combinations of both alleles were then treated with an adenovirus encoding the cre-recombinase (adenoviral Cre (AdCre)) by nasal inhalation to induce Cremediated recombination in the lung epithelium at age 4-7 weeks (Figure 1a ). This treatment is known to infect a small percentage of lung bronchial epithelial cells. After AdCre treatment, the median survival was 11.6 weeks for LSL-Kras G12D Tsc1 L/L mice in contrast to 27.5 weeks for LSL-Kras G12D (alone) mice (log-rank test, P ¼ 0.002). In addition, AdCre-treated LSL-Kras
G12D

Tsc1
L/ þ mice had a median survival of 15.6 weeks, which was also significantly different from both LSL-
L/L mice survived for more than 50 weeks (Figure 1a) .
Pathological analysis of the lung tissue demonstrated that AdCre-treated LSL-Kras G12D Tsc1 L/L mice at 12.5 weeks posttreatment had developed multifocal adenocarcinoma with extensive involvement of the lung parenchyma, consistent with their progressive respiratory insufficiency and death (Figure 1b) . Similarly, AdCre-treated LSL-Kras G12D Tsc1 L/ þ mice also showed multifocal adenocarcinoma of the lung on histological analysis at that age, but this was somewhat less extensive. At 12.5 weeks, AdCre-treated LSL-Kras G12D mice (with wild-type Tsc1) had multiple microscopic foci of adenocarcinoma, which was much less developed, similar to previous reports (Jackson et al., 2001; Ji et al., 2007) . By standard pathological analysis, the lung adenocarcinomas obtained from mice of these three genotypes were indistinguishable. Consistent with their extended survival, AdCre-treated Tsc1 L/L mice had no lung tumors or other pathologies when sampled at 1-year posttreatment. These results indicate that both complete and haploid loss of Tsc1 cooperate significantly with the activating Kras mutation to accelerate lung tumorigenesis. (Figure 1c ). Tsc2 protein levels were also correspondingly reduced, consistent with the chaperone-like effect of Tsc1 on Tsc2 levels (Harrington et al., 2004) .
Phospho-S6-S240/244 (pS6(S240/244)) levels were increased in tumor lysates obtained from both LSLKras G12D Tsc1 L/L and LSL-Kras G12D Tsc1 L/ þ mice, consistent with the activation of mTORC1 due to loss of functional Tsc1/Tsc2 in those tumors, again in contrast to tumor lysates from LSL-Kras G12D mice (Figure 1c ). In addition, phospho-AKT-S473 (pAKT(S473)) levels were also reduced, on average, in both LSL-Kras G12D Tsc1
L/L and LSL-Kras G12D Tsc1 L/ þ mouse lung cancers when compared with LSL-Kras G12D alone lung tumors. This effect is well known in various cell types and systems, as a mechanism of feedback regulation consequent to the loss of Tsc1/Tsc2 and activation of mTORC1 (Zhang et al., 2003; Harrington et al., 2004; . Extracellular signal-regulated kinase (ERK) activation appeared to be higher in LSL-Kras G12D alone lung tumors, as assessed by levels of phospho-ERK(T202/ Y204) (Figure 1c) .
To examine the possibility that lung tumors that developed in LSL-Kras G12D Tsc1 L/ þ mice had undergone genomic deletion or homologous recombination leading to loss of the Tsc1 þ allele, we used the multiplex ligation-dependent probe assay (MLPA) to investigate the copy number of various alleles of Tsc1 in these tumors . Lung tumors from LSL-Kras G12D Tsc1 L/L mice showed a 65% (median) level of conversion of the conditional to the null allele, consistent with recombination at both conditional alleles in tumor cells, and contamination by inflammatory, stromal and vascular cells (Figure 1d) . Similarly,
LSL-Kras
G12D Tsc1 L/ þ mice displayed 52% (median) conversion of the single conditional Tsc1 allele to the null allele. They also showed no major reduction in the copy number of the wild-type ( þ ) allele of Tsc1 (median 41%), suggesting that these tumors developed through a haploinsufficiency mechanism.
Haploid loss of TSC1 is common in human lung cancer specimens As these results suggested that the Tsc1 gene could function as a tumor-suppressor for lung cancer development in the mouse, we explored its involvement in human lung cancer. MLPA was used to assess TSC1 and TSC2 genomic copy number in DNA prepared directly from frozen lung cancer samples collected from 86 patients with NSCLC ( Figure 2 ) . Genomic loss was seen in 19 and 5% of patients for TSC1 and TSC2, respectively ( Figure 2A ). In addition, one patient's cancer displayed a copy number for TSC1 that was 40%, consistent with the complete deletion of TSC1 in tumor cells from this patient, considering stromal and inflammatory cell contamination ( Figure 2B ). L/L mice show accelerated lung cancer development and early mortality. Kaplan-Meier survival curves of mouse cohorts after nasal inhalation of 5 Â 10 6 PFU of AdCre are shown. The median survival was 11.6 weeks for LSL-Kras G12D Tsc1 L/L mice, 15.6 weeks for LSL-Kras G12D Tsc1 L/ þ mice, 27.5 weeks for LSL-Kras G12D mice and more than 1 year for Tsc1 L/L mice. (b) H&E-stained sections of the lung from mice 12.5 weeks after AdCre inoculation shows extensive tumor in both LSL-Kras G12D Tsc1 L/L and LSLKras G12D Tsc1 L/ þ mice. Low-(left) and high-power (right) views are shown. Bar, 100 mm. (c) Immunoblot analysis of protein expression and mTOR signaling in tumors from these mice shows that Tsc1 and Tsc2 expression is reduced in the lung tumor nodules of both LSL-Kras G12D Tsc1 L/L and LSL-Kras G12D Tsc1 L/ þ mice in comparison with tumors from LSL-Kras G12D mice. The pS6(S240/244) expression is increased and pAKT(S473) expression is reduced, consistent with mTORC1 activation in these tumors. pERK levels are higher in LSL-Kras G12D mice, compared with other genotypes. AKT, S6, ERK and actin are all controls. It must be noted that one lung tumor sample was depleted, and was not included in the Tsc2 blot, indicated by an asterisk. (d) MLPA analyses of Tsc1 alleles demonstrate conversion of L to K alleles in both LSL-Kras G12D Tsc1 L/L and LSL-Kras G12D Tsc1 L/ þ tumor nodules. Yellow, red and blue bars indicate the relative amount of wild-type (W), knockout (K) and conditional allele (L), respectively. The four samples at right (panels a-d) are control samples from mice with genotypes KW, KW, LW and LL, respectively. It is noteworthy that the W allele persists in LSL-Kras G12D Tsc1 L/ þ tumor nodules. mTORC1, mammalian target of rapamycin C1; AdCre, adenoviral Cre; H&E, hematoxylin and eosin; pERK, phospho-extracellular signal-regulated kinase; ERK, extracellular signal-regulated kinase; MLPA, multiplex ligation-dependent probe assay.
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In summary, 22% of 86 lung cancer specimens showed evidence of TSC1 and/or TSC2 genomic deletion by MLPA. However, the frequency of TSC2 LOH was so low that this may represent genomic background copy number change, rather than a specific deletion of TSC2.
TSC1/TSC2 loss in human lung cancer cell lines
To explore the loss of TSC1/TSC2 in human lung cancer in greater detail, we surveyed AKT-mTOR signaling in 80 lung cancer cell lines (Supplementary Table 1 ). None of the 80 cell lines were found to display evidence of complete loss of TSC1 or TSC2 by immunoblotting (data not shown). However, 9 (11%) and 2 (3%) of the 80 cell lines showed evidence of LOH for TSC1 or TSC2, respectively, by MLPA analysis (Supplementary Table 1 ). In addition, some cell lines showed high levels of phospho-S6(S240/244) in the absence of serum. However, these same lines generally showed increased activation of pAKT (S473), consistent with this effect being due to the upstream activation of PI3K, PTEN loss or other mutations.
Rapamycin effects in the Kras-Tsc1 mouse lung cancer model As rapamycin is a highly specific therapy that blocks mTORC1 through interaction with FKBP12 (Sabers et al., 1995) , we assessed the potential benefit of rapamycin as a treatment for the LSL-Kras G12D Tsc1
L/L mouse model. Magnetic resonance imaging was used to assess tumor extent before and after a 2-week period of treatment with rapamycin at 6 mg/kg intraperitoneally every other day (Figure 3a) . LSL-Kras G12D Tsc1 L/L mice showed a clear response to rapamycin with an average reduction of 54% in tumor extent, as assessed by magnetic resonance imaging (Figures 3a and 4a) . LSLKras G12D Tsc1 L/ þ tumors showed a smaller response with an overall average reduction of 13% in tumor volume, although several mice showed a much greater response. LSL-Kras G12D mice showed on average stable disease (2% increase) during this period of treatment, whereas LSL-Kras G12D Lkb1 L/L tumors in general showed major progression during rapamycin treatment (average 107% increase). It is noteworthy that placebo-treated control
genotypes (Figure 4a , squares) showed a variable, but generally marked, increase in tumor extent during 2 weeks of observation, whereas a much slower growth rate was seen in placebo-treated LSL-Kras G12D mice, consistent with their markedly different survivals (Figures 1a and 4a) .
Analysis of tumor sections obtained from mice after 1-4 doses of rapamycin showed that both LSL-Kras
G12D
Tsc1
L/L and LSL-Kras G12D tumors showed increased TUNEL (terminal deoxynucleotidyl transferase dUTPbiotin nick-end labeling) positivity consistent with apoptosis after rapamycin treatment (Figures 3b and  4b) . However, this was more pronounced in LSLKras G12D Tsc1 L/L mice than in LSL-Kras G12D mice after 2 and 4 doses of rapamycin (P ¼ 0.028 and P ¼ 0.048, respectively, Figure 4b ). In addition, LSL-Kras
G12D
Tsc1
L/L mice showed evidence of a sustained reduction in proliferation after 2 and 4 doses of rapamycin, in contrast to LSL-Kras G12D mice, although this did not TSC1-KRAS synergy in lung cancer M-C Liang et al reach statistical significance (Figure 4c ). In both types of mice, there was a marked reduction in pS6(S240/244) levels, as assessed by immunohistochemistry. pS6 (S240/ 244) levels were somewhat higher in LSL-Kras G12D Tsc1 L/L mice without treatment, but this did not reach statistical significance (Figure 4d) .
mice treated with rapamycin at 6 mg/kg intraperitoneally every other day showed a significant improvement in survival ( Figure 5) . A striking improvement in survival was seen in LSL-Kras G12D Tsc1 L/L mice (median survival 2.9 vs 18.6 weeks, P ¼ 0.0018). The improvement in survival in LSL-Kras G12D Tsc1 L/ þ mice was somewhat less dramatic but still highly significant (6.9 vs 16.3 weeks, P ¼ 0.002), likely due in part to the slower tumor onset in LSL-Kras G12D Tsc1 L/ þ mice. L/ þ mice. The top three H&E sections were from mice treated for 2 weeks, the bottom mouse was treated for 5 weeks. Bar, 100 mm. (b) Representative photographs of cancers from LSL-Kras G12D Tsc1 L/L and LSL-Kras G12D mice showing apoptosis (TUNEL staining) without treatment, and after two doses of rapamycin. Bar, 100 mm. H&E, hematoxylin and eosin; MRI, magnetic resonance imaging; IP, intraperitoneal; TUNEL, terminal deoxynucleotidyl transferase dUTP-biotin nick-end labeling.
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Discussion
Lung cancer is the most common cause of cancer death for both females and males in the US population (Jemal et al., 2008; Molina et al., 2008) . In the past 10 years, the greatest progress in lung cancer treatment research has been in the identification of a strong correlation between the effectiveness of molecularly targeted therapies (erlotinib, gefitinib) against the EGFR (epidermal growth factor receptor) tyrosine kinase and tumor genotype (activating mutation in EGFR) (Ciardiello and Tortora, 2008) . This experience lends hope to the concept that a detailed molecular characterization of each lung cancer may lead to the identification of unique molecularly targeted treatments designed to exploit the critical oncogenic signaling in each tumor. In this study, we show that lung cancers in the mouse, in which the TSC1/TSC2 function is eliminated or reduced, are uniquely sensitive to a molecularly targeted therapy (rapamycin, RAD001, CCI-779, etc.). However, we observed that complete loss of TSC1/TSC2 is very rare in human lung cancer cell lines we studied, consistent with other recent results (Ding et al., 2008) . We observed major in vivo synergism between activation of Kras and haploid or complete loss of Tsc1 in the development of lung cancer in the mouse. Mice that were either Tsc1 L/L or Tsc1 L/ þ , as well as LSLKras G12D , developed lung cancer on exposure to AdCre at a rate that was 1.8-2.4-fold faster than that observed in mice with LSL-Kras G12D alone (Figure 1a) . Although there were distinct differences in histology and and LSL-Kras G12D Tsc1 L/ þ mice. Kaplan-Meier survival curves of mice of two genotypes treated with either rapamycin (6 mg/kg IP every other day) or placebo, beginning 9 weeks after AdCre inhalation. Rapamycin significantly extended the survival of both LSL-Kras G12D Tsc1 L/L (P ¼ 0.0018) and LSL-Kras G12D Tsc1 L/ þ mice (P ¼ 0.002). IP, intraperitoneal; AdCre, adenoviral Cre. metastatic behavior, their survival was similar to that of AdCre-treated LSL-Kras G12D Lkb1 L/L mice . In addition, it was more limited than that of AdCre-treated mice bearing the LSL-Kras G12D allele, and conditional alleles of p16
INK4a
, p53 or Ink4a/Arf . Both Tsc1 L/L LSL-Kras G12D and Tsc1 L/ þ LSLKras G12D mice demonstrated unique sensitivity to treatment with rapamycin as a single agent, in contrast to mice with Kras activating mutation alone, or LSLKras G12D Lkb1 L/L mice. Survival of both genotypes of Kras-Tsc1 mice was significantly prolonged in response to rapamycin treatment ( Figure 5 ). Our observations that rapamycin treatment causes stable disease (neither growth of tumor nor significant reduction) in LSLKras G12D only mice is similar to a previous report in a different Kras lung model, in which CCI-779 was administered as an mTORC1 inhibitor (Wislez et al., 2005) . In that study, high-dose CCI-779 (20 mg/kg daily for 4 weeks) led to the stabilization of lung tumor extent, with prevention of the appearance of new lung tumors, and a small reduction in tumor size, but mainly due to induction of apoptosis in tumor-infiltrating macrophages (Wislez et al., 2005) .
We found that none of the 80 NSCLC lines examined had a signaling pattern similar to that of TSC1 null or TSC2 null MEFs (Zhang et al., 2003; Harrington et al., 2004) , and that all expressed both TSC1 and TSC2 to some extent. However, we did observe that 22% of human lung cancers and 14% of lung cancer cell lines displayed loss of a single allele of either TSC1 or TSC2 (Figure 2 and Supplementary Table 1), similar to a previous report (Takamochi et al., 2001) . This lack of occurrence of homozygous loss of either TSC1 or TSC2 in human lung cancer is also consistent with a larger body of data indicating that neither gene is a common target for mutation/inactivation in human cancer. This is in striking contrast to other tumor-suppressor genes that regulate mTOR signaling, including LKB1 which is commonly involved in lung cancer Sanchez-Cespedes, 2007; Ding et al., 2008) , and PTEN, less commonly involved in lung cancer, but much more so in colon cancer and glioblastoma. Indeed, the only common adult malignancy in which TSC1 or TSC2 loss has been reported to occur at appreciable frequency is bladder cancer (Hornigold et al., 1999; Adachi et al., 2003; Platt et al., 2009 ). LKB1 and PTEN have broader effects beyond the activation of mTORC1, and this may partially explain their more common involvement in adult cancers.
The reason for this discordance between the lack of involvement of TSC1/TSC2 in human lung cancer and a clear pathogenic role in this mouse model of lung cancer is not clear. One possibility is that because of their location in the genome, TSC1 and TSC2 are uncommon targets for genomic and mutational events. However, second-hit events occur commonly in these genes in tumors of TSC patients (Henske et al., 1996) , arguing against a model of 'relative genomic protection'. A second possibility is the observation that AKT activation is suppressed in tumors from TSC patients, Tsc mouse model tumors and in cell lines in which TSC1/ TSC2 is completely lost (Zhang et al., 2003; Harrington et al., 2004) . This is attributed to various feedback mechanisms, including suppression of IRS function, reduced platelet derived growth factor receptor expression and most recently elucidation of a functional role of the TSC1/TSC2 complex as a cofactor for the kinase activity of mTORC2, the AKT S473 kinase (Zhang et al., 2003; Harrington et al., 2004; . Although this explanation is plausible and may contribute, one speculates why this does not occur in the mouse lung model studied herein, in which the loss of Tsc1 has a clear growth-promoting effect, accelerating the development of lung cancer. It is possible that the combination with Kras activating mutation and/or the timing of this combination is critical in leading to the accelerated lung tumor development in these mice.
The observation that haploid loss of Tsc1 in this mouse model had similar effects in accelerating lung tumorigenesis as complete loss (Figure 1a) , is consistent with a model in which attenuated TSC1/TSC2 function leads to some activation of mTORC1 and complements KRAS mutational activation nearly as well as complete loss. The observation that TSC1 LOH is fairly common in NSCLC patient samples (Takamochi et al., 2001) , is also consistent with a potential growth-promoting effect of haploid expression. Haploinsufficiency is a well-known growth-promoting effect for a number of tumor-suppressor genes, including PTEN, NF1 and those encoding p27Kip1 (Santarosa and Ashworth, 2004; Smilenov, 2006) . In this mouse model, it is possible that ERK-mediated phosphorylation of TSC2, due to activated KRAS, synergizes with haploid loss of TSC1 leading to an inactivation of the TSC1/TSC2 protein complex and mTORC1 activation (Ma et al., 2005) . Two mTORC1 inhibitors have been used in Phase I-II clinical trials in NSCLC patients. Both RAD001 and CC-779 were seen to have an overall 3-5% response rate, although in one trial in which CCI-779 was used, this reached 8% (Gridelli et al., 2008) . Two small Phase I-II combination trials of RAD001 and gefitinib have been completed, with higher response rates (Milton et al., 2007) , and several more trials are ongoing (Gridelli et al., 2008) . Our data suggest the possibility that patients showing response might be those with the haploid expression of TSC1/TSC2 in their lung cancers, but further study is required. Single-agent rapamycin was quite dramatically effective in reducing tumor size and extending survival of LSL-Kras G12D Tsc1 L/L mice, in contrast to limited or no effect on the tumors of mice with the Kras mutation alone or combined with Lkb1 loss (Figures 3a and 5 ). This is consistent with the multiple downstream targets that are influenced by Lkb1 loss (Alessi et al., 2006) . In addition, rapamycin as a single agent has clear activity in both renal epithelial tumors that develop in the mouse models of TSC (Kenerson et al., 2005; Lee et al., 2005; Pollizzi et al., 2009) , and some activity in kidney angiomyolipomas that occur in TSC patients (Bissler et al., 2008) . Thus, this additional experience in both preclinical models and patients supports the concept that rapamycin has particular effectiveness in tumors lacking functional TSC1/TSC2. Although evidently rare, lung cancers that completely lack TSC1/TSC2 are also likely to be very sensitive to rapamycin.
Materials and methods
Mouse cohorts
Mice bearing the Lox-Stop-Lox-Kras G12D allele were provided by Tyler Jacks, Massachusetts Institute of Technology (Cambridge, MA, USA) (Jackson et al., 2001) . Tsc1 L/L mice were generated by floxing exons 17 and 18 of the Tsc1 gene, as described previously (Kwiatkowski et al., 2002 
Tsc1
L/ þ mice were backcrossed to Tsc1 L/L mice. Owing to this breeding scheme, the strain background was mixed for all mice studied. Mice were treated with AdCre by nasal inhalation at 4-7 weeks of age to induce Kras G12D expression and/or inactivation of Tsc1 L alleles by cleavage at Lox sites in the infected respiratory epithelium. The animals were housed in a pathogen-free environment in a barrier facility at the Harvard School of Public Health; all animal experiments performed were approved by the Institutional Animal Care and Use Committee at Harvard Medical School. Mice were terminated when severe dyspnea, weight loss, or other signs of morbidity were observed. The log-rank test was used to compare the survival of different groups of mice.
Lung tissue preparation for histology and immunohistochemical studies The lung tissue was prepared using methods described previously . In brief, mice were killed, the left lung was removed and snap-frozen, while the right lung was inflated and fixed in buffered 10% formalin overnight. Paraffin sections were prepared, and cut at 5 mm for hematoxylin and eosin staining.
Apoptosis was assessed in lung cancer sections by the TUNEL method using the ApopTag Peroxide in situ Apoptosis Detection Kit (Chemicon International, Temecula, CA, USA). To assess cell proliferation, a rabbit polyclonal antibody against Ki67 (1:2500; Vector Lab, Burlingame, CA, USA) was used. An antibody against pS6(S240/244) (New England Biolabs, Ipswich, MA, USA) was also used for immunohistochemistry. TUNEL-and Ki67-positive cells were each counted as the number of positive cells per high power field ( Â 200) in a blinded manner. pS6(S240/244) expression was assessed on a scale from 0 to 4 in tumors in a blinded manner, integrating both strength of the signal and uniformity among cells in the tumors into this score.
In vivo rapamycin treatment Rapamycin treatment was given by intraperitoneal injection every other day at 6 mg/kg (Meikle et al., 2008) . Rapamycin was suspended in 5% (v/v) Tween-80 and 5% (v/v) polyethylene glycol 400. In one cohort, magnetic resonance imaging was used to assess lung tumor involvement before and after rapamycin or control vehicle treatments. Magnetic resonance imaging images were used to quantify the extent of tumor involvement using NIH ImageJ (version 1.33) (Bethesda, MD, USA) as described previously (Li et al., 2007) .
In a second survival cohort, treatment with rapamycin was initiated at 9 weeks after AdCre infection, and continued every other day until survival was terminated because of respiratory difficulties or death.
Cell culture Lung cancer cell lines were obtained from the ATCC (American Type Culture Collection, Manassas, VA, USA) by the Dana-Farber Cancer Institute Lung Cancer Program. All cell lines were maintained in the growth medium recommended by the supplier.
Immunoblotting
Cell and mouse tumor lysates were prepared in lysis buffer (Cell Signaling Technology, Danvers, MA, USA) supplemented with protease and phosphatase inhibitor I and II cocktails (Calbiochem, San Diego, CA, USA), using a Dounce homogenizer for the tumor nodules, and clarified by centrifugation at 13 000 g for 10 min.
Protein concentrations were determined using the DC Protein Assay (Bio-Rad, Hercules, CA, USA) and equivalent amounts (50 mg) were subjected to SDS-PAGE on 4-12% gradient gels (Invitrogen, Carlsbad, CA, USA), transferred into polyvinylidene fluoride membranes and detected by immunoblotting with antibodies indicated using SuperSignal West Pico Chemiluminescent substrate (Pierce Biotechnology, Rockford, IL, USA). Antibodies used were against: TSC1, pAKT(S473), AKT, pS6(S240/244), pS6(S235/236), S6, phospho-ERK(T202/Y204), ERK (Cell Signaling Technology); TSC2, (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
MLPA for analysis of TSC1/TSC2 for LOH, and genotyping of the Tsc1 allele in mouse samples Multiplex ligation-dependent probe assay analysis for LOH in TSC1 and TSC2 was conducted using a set of 23 homemade probes, consisting of 10 probes in TSC1, 10 probes in TSC2 and 3 control probes from different chromosomes, as described previously . MLPA products were quantified by capillary electrophoresis on an ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA), using GeneMapper v3.5 (ABI). Excel programs were used to transform the peak height data to normalized values, such that the average signal from control samples after normalization was 1. We classified cases as demonstrating LOH for TSC1 or TSC2 when the average signal from probes for those genes was X0.2 lower than that from other probes in the set, and a comparison of signal intensity was significant at Po0.001 in a two-sided t-test.
To assess the genotype of mouse DNA samples from mice bearing combinations of the floxed (L), null (K) and wild-type (W) alleles, a panel of nine MLPA probes was generated to interrogate these three alleles, including four control probes and probes specific for each allele. MLPA analysis was performed on DNA samples obtained from mice of known genotypes as controls, and then performed on tumor nodules to determine the percentage of each allele present, after normalization and comparison with control samples. Oligonucleotide sequences for the probe sets and details are available on request.
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